Drug Development

Transgene unveils a scalable mpox vaccine using its cancer immunotherapy tech. Can this strategic pivot disrupt the market and fix global supply gaps?

A new license for C-Ray Therapeutics is more than a permit; it's a key move in Beijing's strategy to dominate the high-stakes radiopharmaceutical market.

ARS Pharmaceuticals' needle-free allergy spray, neffy, faces a major setback with commercial insurers, forcing a strategic pivot toward fiscal discipline.

Passage Bio finds a lifeline in a reverse merger with Remix Therapeutics, a rising RNA star. But what does this deal truly mean for shareholders and the future of cancer treatment?

The FDA has approved TRYNGOLZA, the first drug to reduce triglycerides and acute pancreatitis risk, marking a new era for millions and a pivotal moment for Ionis.

A small biotech reports its novel curcumin gel eases sickle cell pain. But its strategy of pre-approval access via pharmacies is a high-stakes economic gamble.

Promising Phase 2 data for AP-101 shows it slows ALS progression by targeting a key toxic protein, offering new hope beyond purely genetic approaches.

The $2B market for chronic hives is exploding, with new drugs from Sanofi, Celldex, and Novartis creating a seismic shift for patients and investors.

A new RNA therapy for obesity is advancing in trials. It promises to reduce harmful visceral fat, preserve muscle, and may only require a twice-yearly dose.

A new preclinical platform from HKeyBio aims to solve key bottlenecks in developing drugs for debilitating gut disorders. Is this the execution-focused approach the industry needs?

A novel drug for glioblastoma enters a revolutionary trial, but the real story is the mission-driven company behind it, rewriting the rules of drug development.

Calidi Biotherapeutics' RedTail platform uses a virus to make tumors produce their own medicine, a strategy that could finally defeat solid cancers.

Heparin, a trusted blood thinner, can trigger a fatal immune reaction. A small biotech's novel drug is now taking the global stage with a targeted solution.

Imbria's ninerafaxstat gains FDA Orphan Drug status for nHCM, a rare heart condition. This strategic win pits its unique metabolic approach against rivals.

A key FDA alignment for zervimesine not only de-risks a pivotal trial but signals a new era for treating the devastating psychosis of an overlooked dementia.

An alliance of biopharma innovators is set to discuss a critical hurdle in medicine: delivering RNA therapies to tissues beyond the liver, a key to unlocking new treatments.

Novartis is betting nearly $2 billion on Antares Therapeutics' novel platform to conquer historically 'undruggable' cancer targets, a move that could redefine oncology.

Ollin Biosciences secured $330M to challenge giants like Roche and Regeneron. Their next-gen antibody shows early promise in treating vision loss.

As Julie Kim becomes Takeda's new CEO, she inherits a robust pipeline and a fortified board, signaling a strategic shift toward executional excellence.

A massive $115M funding round fuels UK biotech RQ Bio's quest to replace the annual flu shot for the vulnerable with a single, season-long antibody treatment.